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Abstract.  Cultured bovine capillary endothelial (BCE) 
cells synthesize heparan  sulfate proteoglycans (HSPG), 
which are both secreted into the culture medium and 
deposited in the cell layer.  The nonsoluble HSPGs can 
be isolated as two predominant  species: a larger 800- 
kD HSPG, which is recovered from preparations  of 
extracellular matrix,  and a 250-kD HSPG, which is 
solubilized by nonionic detergent extraction of the 
cells. Both HSPG species bind bFGE  ~25I-bFGF bound 
to BCE cell cultures is readily released by either 
heparinase  or plasmin.  When released by plasmin,  the 
growth factor is recovered from the incubation 
medium as a complex with the partly degraded high 
molecular mass HSPG. Endogenous bFGF activity is 
released by a proteolytic treatment of cultured BCE 
cells. 
The bFGF-binding HSPGs are also released when 
cultures are incubated with the inactive proenzyme 
plasminogen.  Under such experimental conditions, the 
release of the extracellular proteoglycans can be en- 
hanced by treating the cells either with bFGF, which 
increases the plasminogen activating activity expressed 
by the cells, or decreased by treating the cells with 
transforming growth factor beta, which decreases the 
plasminogen activating activity of the cells.  Specific 
immune antibodies raised against bovine urokinase 
also block the release of HSPG from BCE cell cul- 
tures.  We propose that this plasminogen activa- 
tor-mediated proteolysis provides a mechanism  for the 
release of biologically active bFGF-HSPG complexes 
from the extracellular matrix and that bFGF release 
can be regulated by the balance between factors affect- 
ing the pericellular proteolytic activity. 
B 
ASIC fibroblast  growth factor (bFGF) is a multifunc- 
tional growth factor present in several tissues in vivo 
and is synthesized by a number of cell types in vitro 
(15, 32).  It affects the growth and  differentiation  of many 
cells of ectodermal or mesodermal origin via a high affinity 
membrane receptor (29, 30, 35, 36).  bFGF is a potent en- 
dothelial growth factor in vitro and is capable of inducing an- 
giogenesis in vivo at nanogram  amounts  (21). It is thought 
to function  as an autocrine factor in cultures  of endothelial 
cells (46, 48). 
Pathways for the release of bFGF have so far remained un- 
characterized.  The precursor molecule does not have a clas- 
sical signal sequence which would mediate its secretion into 
the extracellular  space (1). However, bFGF is recovered from 
extracellular  matrix both in vitro and in vivo (2, 12, 49, 52) 
and can be released from its  binding  sites  by heparinase 
digestion  or by trypsin (3,  52).  Extracellular  matrix  may 
serve as a reservoir for bFGF since binding to matrix struc- 
tures  is  responsible  for the  long-term  stimulation  of en- 
O. Saksela's current address is Department of Virology, University of Hel- 
sinki, Haartmanikatu 3, 00290 Helsinki, Finland. Please address corre- 
spondence to D. Rifkin. 
dothelial cells even after a short exposure to the growth fac- 
tor (10). 
bFGF is characterized  by its high affinity towards heparin 
and has been shown to bind to heparan sulfates secreted into 
the growth medium by cultured endothelial cells (43). Hepa- 
ran sulfate is an abundant  component of most extracellular 
structures  and it has been suggested to play a role in cellular 
interactions  and  in growth control during  morphogenesis, 
cell differentiation,  and growth (5, 19, 45, 51). Cultured aor- 
tic endothelial  cells synthesize three different types of hepa- 
ran sulfate: a cell membrane-associated heparan sulfate pro- 
teoglycan (HSPG), 1 an extracellular matrix-associated HSPG, 
and a small heparan sulfate found only in the culture medium 
(23, 24). The protein core of the cell-associated HSPGs is 
sensitive to degradation by wide-spectrum serine proteinases 
such as trypsin. Degradation  of the core protein leads to the 
release of heparan  sulfate chains  still bound to proteinase- 
resistant  core protein peptides (38). 
1.  Abbreviations  used in  this paper:  BCE,  bovine capillary endothelial; 
HSPG,  heparan sulfate proteoglycan;  KIU,  Kallikrein  inhibitor units; PA, 
plasminogen activator; PAI-1, type I plasminogen activator inhibitor; TGF/~, 
transforming growth factor/3; tPA, tissue-type plasminogen activator; uPA, 
urokinase-type plasminogen activator. 
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much like that of trypsin is plasmin, which is formed from 
the inactive precursor molecule plasminogen by proteolytic 
activation (40).  Two separate serine proteinases capable of 
effectively activating plasminogen have been characterized. 
They are the urokinase-type plasminogen activator (uPA), 
usually associated with cell migration and tissue destruction, 
and the tissue-type plasminogen activator (tPA),  associated 
with thrombolysis and possibly prohormone activation and 
release (6).  The activity of plasminogen activators (PAs) is 
partly regulated by highly specific proteinase inhibitors ex- 
pressed in vitro by a variety of cell types (41). The principal 
inhibitor released by endothelial cells is the type 1 plasmino- 
gen activator inhibitor (PAI-1), which reacts  rapidly with 
both uPA and tPA. Due to the high levels of plasmin inhibi- 
tors found in the circulation and in most extraceUular  fluids 
it is likely that plasmin function is restricted to sites where 
the active enzyme is unavailable to its soluble inhibitors and 
where PA is not subject to inactivation by its inhibitor (PAI- 
D. Therefore, the modulation of the local release of PA and 
its  inhibitor may be  the crucial  step  in the regulation of 
plasmin-mediated proteolysis. 
In the present article we propose a role for the plasmino- 
gen activation cascade in the release of matrix-bound bFGF 
from the heparan sulfate-rich extracellular milieu of capil- 
lary endothelial cells. The soluble bFGF is found as a com- 
plex with HSPG. The release of bFGF-binding HSPG com- 
plexes can be modulated by the PA activity expressed by the 
cells themselves. The findings indicate a primary role for PA 
and its inhibitor in mediating matrix breakdown, which in 
turn may affect the release of matrix-bound growth factors. 
Materials and Methods 
Reagents 
bFGF was either purified from full-term human placentas (33,  37) or was 
prepared by recombinant techniques in Escherichia coli and was a gift from 
Dr. A. Sommer (Synergen Inc., Boulder, CO) (50). Both preparations gave 
identical results with respect to their ability to bind heparan sulfate. Plas- 
minogen was purified from outdated human plasma as described elsewhere 
(7).  Plasmin,  trypsin, heparirmse, ehondroitinase ABe,  methylumberyl- 
liferum-b-xyloside, heparin,  guanidine,  urea,  and  protein A-Sepharose 
were obtained from Sigma Chemical Co.  (St.  Louis, MO) and were the 
highest grade available.  DEAE-cellulose (DE-52) was from Whatman Inc. 
(Clifton, NJ).  Antibodies against bFGF were raised in rabbits and their 
specificity was confirmed as described earlier (22, 32). These antibodies 
recognize bFGF but not other heparin-binding growth factors. Antibodies 
against bovine urukinase were raised in rabbits by injecting the animals with 
urukinase purified from cultures of bovine kidney epithelial cells. IgG was 
further purified  from the  serum by  affinity chromatography on protein 
G-Sepharuse according to the manufacturer's procedure (Pharmacia Fine 
Chemicals, Uppsala, Sweden). The IgG preparation at a concentration of 
500 #g/ml completely inhibited the urokinase-dependent activity produced 
by l0  s bovine capillary endothelial (BCE) cells placed in contact with ra- 
diolabeled fibrin substrate for 4 h in plasminogen-contaiulng medium. The 
antibodies only partially neutralized human urokinase activity.  Polyclonal 
antibodies against the human uPA and tPA were obtained from American 
Diagnostica (New York,  NY). 
Cell Cultures 
BCE cells were isolated from the adrenal cortex by the method of Folkman 
et al. (11), and the cloned ceils were identified as endothelial cells by stain- 
ing for factor VHI-related antigen (11). The cells were grown in alpha- 
modified MEM supplemented with 5 % newborn calf serum and antibiotics 
and used for experiments between passages 6 and 15. When indicated, the 
cell cultures were labeled with 35SO4 (40 #Ci/ml; New England Nuclear, 
Boston, MA) for 16 h  in serum-free alpha-modified MEM. 
Isolation of the Metabolically  Labeled Proteoglycans 
35SO4-1abeled cells were extracted with 4 M guanidine-HC1 in 50 mM Na- 
acetate buffer, pH 6.0, containing 2% Triton X-100,  1 mM PMSE and 200 
Kallikrein inhibitor units (KIU)/ml aprotinin (17). After a 6-h incubation at 
4°C, the extract was applied to a column of Sepharose G-25 (0.6  ×  10 cm) 
equilibrated with 8 M urea in 50 mM Na-acetate buffer, pH 6.0, containing 
0.5% Triton X-100, 0.15 M NaC1, PMSF, and aprotinin and eluted from the 
column with the same buffer.  Fractions containing the radioactivity were 
pooled and bound to a DE-52 column (0.5  x  2 cm) equilibrated with the 
8 M urea buffer. The bound radioactivity was eluted with a 0.15-1.0 M NaCI 
gradient in the above buffer. Labeled material eluting between 0.20 and 0.75 
M  NaC1 was pooled and used for further experiments as described in the 
text. 
Binding of the Isolated 3~SO~-labeled  Proteoglycans 
to bFGF 
bFGF was added to samples of the isolated proteoglycans and incubated at 
37°C for 15 min. Complexes that formed were precipitated by adding rabbit 
anti-bFGF IgG immobilized on protein A-Sepharose beads. The pellet was 
washed with PBS (0.01 M I)O4, 0.15 M NaC1, pH 7.4), and the bound mol- 
ecules were eluted with reducing sample buffer. The samples were analyzed 
by electrophoresis in a 3-16% SDS-polyacrylamide slab gel (25), and the 
radiolabeled molecules were visualized by autoradiography. 
Xyloside Treatment of  BCE Cells 
Cells were trypsinized and grown in the presence of 1.0 mM methylumberyl- 
liferum-b-xyloside  in alpha-modified MEM supplemented with 5 % calf se- 
rum (47).  Fresh medium containing the xyloside was added to the cells 
twice a  week.  The xyloside was added to the medium during overnight 
labeling of the cells. The growth rate and morphology of BCE cells in the 
presence of the xyloside were comparable with those seen in the control 
cultures. 
Binding of~l-bFGF to BCE Cells 
bFGF was iodinated as described by Moscatelli (29).  12SI-bFGF (specific 
activity 1,100 cpm/fmol) mixed with cold bFGF in PBS containing 10 mM 
Hepes and 0.15%  gelatin was added to BCE cells grown on 35-ram dishes 
and incubated at 40C for 30 rain.  Unbound bFGF was removed, and the 
cells were washed thrice with cold PBS. The cell cultures were treated as 
described in the text. 
Triton X-IO0 Extraction of  BCE Cells and Preparation 
of the Extracellular Matrix 
Radiolabeled cultures were washed twice with cold PBS and treated with 
0.5 % Triton X-100 in 10 mM Tris-HC! buffer, pH 7.4. Extraction of  the cells 
was carried out at 4°C for 30 min on a shaker. The Triton X-100 extract 
was collected, and insoluble material was removed by  centrifugation at 
10,000 g  for 10 min. The dishes were further incubated at 40C with the 
above detergent solution containing 20 mM NI-L,OH, washed thrice with 
PBS, and used for experiments as indicated in the text. Both detergent solu- 
tions contained 2 mM PMSF and 200 KIU/ml aprotinln. 
PA Assays 
Cell-associated PA activity was measured in cells incubated for  16 h  in 
serum-free medium and then extracted in 0.5% Triton X-100 in 0.1 M Tris- 
HCI, pH 8.1. Activity was quantitated by the 125I-fibrin plate assay as de- 
scribed (16) and expressed in Ploug units using purified urokinase (Calbio- 
chem-Behring Corp., La Jolla, CA) as a standard. 
Results 
Isolation of  bFGF-binding HSPG from BCE Cells 
We  have previously  demonstrated that cultured BCE  cells 
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extracts of  BCE cells. Cultures of  confluent cells were labeled over- 
night, and bFGF-binding molecules were isolated as described  in 
Materials and Methods and analyzed in SDS-PAGE followed by au- 
toradiography (lane a). (Lane b) Material bound to anti-bFGF IgG 
without  addition  of bFGF;  (lane  c)  material  bound  to  protein 
A-Sepharose particles alone; (lanes d and e) material remaining af- 
ter bound  molecules  were  treated  with  chondroitinase  ABC  or 
heparinase, respectively; (lane f) molecules recovered from condi- 
tioned  medium  of  BCE  cells  by  absorption  with  antibody- 
immobilized bFGF; (lane g) heparinase digestion of material from 
lane f. 
raining the bFGF-glycosaminoglycan complexes were dis- 
persed in PBS, and the samples were treated with 2 IU/ml 
of chondroitinase  ABC  (Fig.  1,  lane  d)  or  2  IU/ml  of 
heparinase (Fig.  1, lane e) for 3 h  at 37°C in the presence 
of 200 KIU/ml of aprotinin.  After the incubation,  sample 
buffer was added,  and the material was analyzed by SDS- 
PAGE. The results demonstrate that all bFGF-bound 35SO4- 
labeled molecules were degraded by heparinase but not by 
chondroitinase ABC. 
As shown previously (43), molecules of a similar size and 
sensitive to heparinase digestion can be recovered from the 
conditioned medium of these cultures by direct absorption 
with antibody-immobilized bFGF (Fig.  1, lanes f  and g). 
Localization of the bFGF-binding Molecules in 
Cultures of  BCE Cells 
To  determine  the  cellular  localization  of the  two  bFGF- 
binding heparan sulfates, the cells were extracted with 0.5 % 
Triton X-100.  This procedure removes the cytoplasmic and 
membrane structures and leaves a  well-characterized com- 
plex of extracellular matrix components bound to the growth 
substratum (18).  The molecules that remain associated with 
the  matrix  can,  in  turn,  be  solubilized  with  guanidine. 
35SO4-1abeled BCE cell cultures were separated into Triton 
X-100-soluble  and  -insoluble  fractions,  and  the  insoluble 
synthesize  and  release  into  the  growth  medium  HSPGs 
which bind bFGF (43). To study further the origin and me- 
tabolism of these soluble bFGF-binding molecules, we iso- 
lated HSPGs from the cell layer and characterized the mech- 
anisms involved in their release. 
BCE cell cultures labeled with 35SO4 were extracted with 
guanidine, and the extracts were changed to urea by chroma- 
tography through a Sepharose G-25 column, bound to DE- 
52, and eluted with a salt gradient. Most of the radioactivity 
eluted  between  0.25  and  0.75 M  NaCl  (not  shown).  The 
eluted radiolabeled material was pooled, and the sample was 
adjusted with water to give final concentrations of 0.16  M 
NaC1 and 2.7 M urea. The glycosaminoglycans were bound 
to bFGF by adding the growth factor to a sample of the above 
eluate.  The complexes of HSPG and bFGF which formed 
were precipitated with anti-bFGF immobilized on protein 
A-Sepharose and analyzed by SDS-PAGE (Fig.  1, lane a). 
Two bands of radioactivity were observed, one correspond- 
ing to a molecule with a molecular mass of 800 kD and the 
second at a position corresponding to 250 kD. Barely detect- 
able amounts of the 35SO4-1abeled material bound to anti- 
bFGF beads without prior addition of bFGF to the samples 
(Fig.  1,  lane b) or to protein A-Sepharose particles alone 
(Fig.  1,  lane  c).  To demonstrate the  nature  of the  bound 
35SO4-1abeled molecules,  protein  A-Sepharose  beads con- 
Figure 2.  Demonstration  of the localization of the bFGF-binding 
HSPGs. 35SO4-1abeled  cultures of BCE cells were treated with Tri- 
ton  X-100 and  guanidine-urea  as  described  in  Materials  and 
Methods,  and the  solubilized,  radiolabeled  bFGF-binding  mole- 
cules were analyzed  in SDS-PAGE followed by autoradiography. 
(Lane a) Guanidine-urea extract of isolated matrix; (lane c) Triton 
X-100 extract of cells; (lanes b and d) material isolated as in lanes 
a and c, respectively, but after heparinase treatment of intact cells 
before extraction of the cultures;  (lanes e and g) material isolated 
as in lanes a and c, respectively, from cultures grown in the pres- 
ence of methylumberylliferum-beta-xyloside;  (lanes land h) mate- 
rial  isolated  from  methylumberylliferum-beta-xyloside-treated 
cells as in lanes e and g, respectively, but after heparinase pretreat- 
merit of the cells. 
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cell extraction. The radiolabeled molecules from the Triton 
X-100 extract and from the guanidine-urea extract were then 
bound to DE-52, eluted with 0.5 M NaC1, bound to immobi- 
lized bFGF, and analyzed by SDS-PAGE (Fig. 2). The high 
molecular mass 800-kD heparan sulfate was recovered from 
the  Triton X-100-insoluble  fraction,  whereas  the  smaller 
250-kD heparan sulfate was solubilized by the Triton X-100 
treatment.  (Fig. 2, lanes a  and c). 
To demonstrate the extracellular nature of both of the mol- 
ecules, 5 IU/ml of heparinase was added to the cells for the 
last 3 h of metabolic labeling.  After the labeling, the cells 
were washed thrice with cold PBS to remove the enzyme, 
and separated into Triton X-100-soluble and -insoluble frac- 
tions by adding cold 0.5% Triton X-100 at 4°C as described. 
The insoluble molecules were then extracted with 4 M guani- 
dine,  and  the bFGF-binding  molecules were purified and 
characterized as above. The heparinase treatment resulted in 
the disappearance of both the Triton X-100-insoluble and 
-soluble heparan sulfates (Fig. 2, lanes b and d). These re- 
suits suggest that the majority of the smaller bFGF-binding 
heparan sulfate is located at the exterior of the cell in a Triton 
X-100-extractable,  heparinase-sensitive  form.  The  larger 
35SO4-1abeled molecule appears to be a  component of the 
extracellular matrix and can also be degraded by the added 
heparinase. 
The 800-kD bFGF-binding heparan sulfate located both in 
the conditioned medium  (43)  and  in  the cell extract (not 
shown) could be labeled with psS]methionine, thus demon- 
strating  the  presence  of a  protein  core  in  the  molecule, 
whereas the smaller heparan sulfate could not be labeled 
with [35S]methionine (not shown). To demonstrate that both 
of the bFGF-bound heparan sulfates were proteoglycans or 
were derived from proteoglycans, BCE cells were grown in 
the presence of beta-xylosides, which can act as primers for 
the synthesis of the proteoglycan polysaccharide side chains. 
The enzyme xylosyltransferase is responsible for the addi- 
tion of the first sugar to the proteoglycan core protein during 
synthesis of the polysaccharide side chains (47). The pres- 
ence of beta-xylosides leads to synthesis of free glycosamino- 
glycan chains.  Addition of 1 mM  methylumberylliferum- 
beta-xyloside to the growth medium of the cells resulted in 
an almost total disappearance of both of the bFGF-binding 
high molecular mass heparan sulfate species from the Triton 
X-100-soluble  and  -insoluble  fractions  (compare  Fig.  2, 
lanes e and g, with lanes a  and c, which were obtained in 
the absence of xylosides). 
Release of the bFGF-binding HSPG by 
Plasmin Digestion 
The sensitivity of the bFGF-binding extracellular HSPGs to 
release  by  proteolysis  was. tested  by  adding  increasing 
amounts  of plasmin  (final  concentrations  0.1,  1,  and  10 
/xg/ml) to cultures of BCE cells. After a 20-rain incubation, 
the medium was collected, plasmin activity was inhibited by 
addition of aprotinin (100 KIU/ml), and the released mole- 
cules were bound to immobilized bFGE  As shown in Fig. 
3,  lanes  a-c,  bFGF-binding  35SO4-1abeled HSPGs  were 
released from the cells under these conditions. The high mo- 
lecular mass species had a slightly smaller molecular mass 
than the corresponding bFGF-binding  molecule from the 
whole cell extracts or from the matrix preparations. 
Figure 3. Release of  bFGF-HSPG complexes by plasmin digestion. 
FGF-binding HSPGs were isolated as described in Materials and 
Methods after plasmin treatment of 35SO4-1abeled cells and ana- 
lyzed by SDS-PAGE followed by autoradiography. (Lane a) 0.1 
#g/ml plasmin; (lane b) 1/~g/ml plasmin; (lane c) 10 ttg/ml plas- 
min. (Lanes d-g) Release by plasmin of 125I-bFGF from cultures 
of  BCE cells: (lane d) no plasmin; (lane e) 0.1/zg/ml plasmin; (lane 
f) 1/zg/ml plasmin; (lane g) 10/~g/ml  plasmin. (Lanes h-j) Release 
of bound ~25I-labeled  bFGF by heparinase treatment: (lane h) 0.1 
IU/ml hepadnase;  (lane t) 1 IU/ml heparinase; (lane j) 10 IU/ml 
heparinase. Material in lanes d-j was concentrated by binding to 
protein A-immobilized anti-bFGF IgG. 
Release of 12~l-bFGF  from BCE by Plasmin and 
Heparinase Treatment 
To test whether plasmin could release the cell-bound bFGF 
as a complex with HSPG, the following experiment was per- 
formed. 5/xg/ml of bFGF mixed with  10,000 cpm/ml  ~25I- 
bFGF  (specific  activity  1,100  cpm/fmol)  was  bound  to 
35SO4-1abeled BCE  cells grown  on  35-mm  dishes  as  de- 
scribed in Materials and Methods.  After washing the cells 
several times with PBS to remove unbound growth factor, the 
cells were incubated with increasing concentrations of plas- 
min (0.1, 1, and 10 #g/ml) in PBS for 20 min at 37°C.  After 
the incubation, plasmin activity was inhibited by addition of 
aprotinin. The released material was absorbed by anti-bFGF 
IgG immobilized on protein A-Sepharose particles and ana- 
lyzed by SDS-PAGE. As shown in Fig. 3, lanes e-g, bFGF 
was rapidly released from the cell culture with low concen- 
trations of plasmin. The precipitation of the plasmin-released 
bFGF with anti-bFGF IgG resulted in coprecipitation of the 
high molecular mass 35SO4-1abeled HSPG. The fact that the 
bFGF was not degraded under these conditions is consistent 
with our earlier observation that bFGF complexed to HSPG 
is resistant to proteolysis by trypsin or plasmin (43). Hepa- 
rinase (0.1,  1, and 10 IU/ml) also readily released the cell- 
bound bFGF.  However, no  35SO4-1abeled molecules  were 
detectable in the SDS-PAGE analysis of  the heparinase relea- 
sate (Fig.  3, lanes h-j). 
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Protease-released Material  from BCE Cells 
Although the uncomplexed bFGF is readily degraded by pro- 
teinases, previous experiments demonstrated (43) that bFGF 
bound to HSPG is protected from proteolysis. Therefore, we 
next wanted to test whether biologically active endogenous 
bFGF could be released from the matrix by proteolysis. Two 
150-ram dishes of confluent BCE cells were labeled with 
35SO4 and treated with 5  mg/ml trypsin for 1 min at 37°C. 
The enzyme was inhibited by addition of soybean trypsin in- 
hibitor (20 mg/ml) and aprotinin (400 KIU/ml). The trypsin 
releasate was collected, and the few detached cells were re- 
moved by centrifugation at 2,000 g for 15 min. The released 
molecules were bound to a 2-ml DE-52 column equilibrated 
with PBS. The column was washed with 0.25 M NaCI in 0.01 
M  PO4 buffer, pH 7.4, and the remaining molecules were 
eluted with 0.5 M  NaCI in the same buffer. Fractions with 
the highest radioactivity were adjusted to 0.15 M NaCI with 
water and tested for the presence of bFGF by assaying their 
ability to stimulate PA production in BCE cells (32, 33, 37). 
To do this, aliquots of the samples were mixed either with 
anti-bFGF IgG (200/zg/ml) or with nonimmune rabbit IgG 
(200 #g/ml),  incubated at 37°C for 30 min,  and added to 
BCE cells grown in 24-well Linbro plates. After a 16-h incu- 
bation, the cells were extracted, and the PA activity in the 
samples was measured. As shown in Fig. 4, the endogenous 
level in the BCE cells was quite low (bar a) but could be 
stimulated 20-fold by the addition of recombinant bFGF (bar 
e). The nonimmune IgG did not inhibit the induction (bar  f), 
while the immune IgG was capable of  blocking the PA induc- 
tion in BCE cells observed with 20/~g/ml recombinant bFGF 
(bar g). Control experiments demonstrated that the nonim- 
mune IgG did not affect PA production in the cultures (bar h), 
whereas the immune IgG lowered the basic PA level in the 
cells. The DE-52 eluate stimulated PA production eightfold 
(bar b). The activity of  the eluate was not inhibited by nonim- 
mune IgG, while immune IgG had a clear effect on the ex- 
pressed PA activity (bars c and d). These immune IgGs have 
been shown to be specific for bFGF and not to cross react 
with other heparin-binding growth factors (22). The above 
results indicate that proteolytic activity can release bFGF 
from BCE cells in a form complexed to HSPGs and that this 
bFGF is biologically active. They also demonstrate that the 
cells express a bFGF-dependent basic PA activity which is 
sensitive to the effect of neutralizing anti-bFGF IgG (46). 
Effect of  bFGF  and Transforming Growth 
Factor [3 (TGF/3) on the Release of  the bFGF-binding 
ExtraceUular HSPGs by PA-mediated Proteolysis 
Since plasmin was able to cause the release of the bFGF- 
binding HSPGs from BCE cells, we tested whether the en- 
dogenous plasmin activity of BCE cell cultures, mediated 
through the secretion of PA and activation of plasminogen, 
could  affect  the  release  of  extracellular  bFGF-binding 
HSPGs.  To test this,  BCE  cells  were treated either with 
bFGF or with TGF/~. These growth factors have opposite 
effects on the PA activity expressed by BCE cells (42). While 
bFGF enhances  PA  synthesis,  treatment of the cells with 
TGF/3 reduces PA synthesis and stimulates PAI-1 synthesis. 
As demonstrated in Fig. 5, the inclusion of nanogram con- 
centrations of TGF/g-1 in  the  serum-free growth  medium 
Figure 4. Release by proteolysis of biologically active endogenous 
bFGF from cultures of BCE cells.  Confluent cultures of 35SO4- 
labeled BCE cells were treated with trypsin, DE-52 binding mate- 
rial was isolated, and fractions were tested for PA-stimulating  activ- 
ity as described in the text. PA activity expressed by control cultures 
(bar a) and by cultures with various additions- (bar b) DE-52 elu- 
ate, (bar c) eluate and nonimmune IgG (200 #g/ml), (bar d) eluate 
and anti-bFGF IgG (200/zg/ml),  (bar e) 20 ng/ml of hFGE (bar 
f) 20 ng/ml of bFGF and 200 ~g/ml of nonimmune IgG, (bar g) 
20 ng/ml of  bFGF and 200 #g/ml of anti-bFGF IgG, (bar h) nonim- 
mune IgG (200 #g/ml),  (bar i) anti-bFGF IgG (200/zg/ml)-is 
shown. 
caused a dramatic decrease in the cell-associated PA activity, 
while the inclusion of  bFGF in the culture medium increased 
PA activity. In the proteolytically active bFGF-treated cul- 
tures,  the  amount  of the  released  metabolically  labeled 
HSPGs was proportional to the plasminogen concentration 
in the culture medium (Fig. 6, lanes a-c). When 4 ng/ml of 
TGFfl-1 was added to the culture medium during the meta- 
bolic labeling of the cells and matrix, the release of HSPGs, 
mediated by added plasminogen, was substantially inhibited 
(Fig. 6, lanes d-f). Both TGF/~- and hFGF-treated cells con- 
tained approximately the same total amount of  bFGF-binding 
HSPGs available for plasmin digestion after 16 h labeling of 
the cultures, as shown by incubating the cells with plasmin 
rather than plasminogen (Fig.  6,  lanes g-h).  These results 
demonstrate  that  the  release  of  bFGF-binding  matrix 
HSPGs, some of which are probably complexed with the en- 
dogenous bFGE depends upon the concentration of plasmin 
generated in the cultures which is a reflection of the endoge- 
nous pericellular activity. 
To further document the role of  urokinase as the regulatory 
enzyme in HSPG release in these experiments, antibodies 
against bovine urokinase were raised in rabbits. The purified 
IgG-molecules were used at concentrations of 100, 200, and 
500/zg/ml to inhibit the release of 35SO4-1abeled molecules 
from cultured BCE cells.  Confluent cultures of BCE cells 
were labeled for 16 h under serum-free conditions, washed 
thrice, and further incubated for 3 h. The highest concentra- 
tion of anti-bovine urokinase antibodies almost completely 
blocked the accumulation of bFGF-binding molecules to the 
culture medium (Fig. 7). Polyclonal IgG antibodies against 
human urokinase or against human tPA or preparations of 
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of BCE cells. Increasing amounts of bFGF or TGFI3 were added 
under serum-free conditions to cultures of BCE ceils, and PA activ- 
ity in the cell extracts was determined after a 16-h incubation. (Bars 
a-i) Control cells, 0.3 ng/ml bFGF, 1 ng/ml bFGF, 3 ng/ml bFGF, 
10 ng/ml bFGF, 0.1 ng/ml TGF/5, 0.3 ng/ml TGF/5, 1 ng/ml TGF/3, 
and 3 ng/ml TGFI3, respectively. The data shown in Figs. 4 and 5 
are based on quadruplicate  PA determinations  from two indepen- 
dent experiments. The variation within experimental or control as- 
says was never >20%. 
nonimmune rabbit IgG at similar concentrations had no de- 
tectable  effect on  the  release  (data  not  shown),  whereas 
nonimmune  rabbit  serum  at  a  1:20  dilution  slightly  de- 
creased the accumulation of radiolabeled molecules to the 
culture medium (Fig. 7). 
Combined Effect of TGF{3 and bFGF on the 
Release of  HSPG 
We have demonstrated in an earlier study that pretreatment 
of BCE ceils with TGF~ decreases or completely prevents 
the rapid stimulation of PA activity by bFGF (42). Since the 
release of HSPG appears to be closely dependent on the PA 
activity  expressed  by  BCE  ceils,  we  wanted  to  examine 
whether a similar kind of inhibitory effect by TGF/3 pretreat- 
merit could be detected on the release of HSPG from BCE 
ceils. Incubation of the cells with TGF/3 for 6  h  before the 
addition of bFGF decreased the amount of released HSPG 
compared with release from cultures incubated in medium 
alone or with bFGF (Fig.  8).  The release was close to that 
seen in cultures treated with TGF/5 alone. 
Discussion 
bFGF is synthesized by endothelial cells in culture (32, 48, 
52) and has been shown to affect several cellular properties 
in an autocrine fashion (46). The growth factor binds readily 
to extracellular matrix structures and can be recovered from 
preparations of isolated matrix from cultures of endothelial 
cells (29, 52). We have previously shown that soluble hepa- 
ran sulfate molecules synthesized by endothelial cells bind 
bFGF and protect it from proteolytic inactivation (43). In the 
Figure 6. Effect ofbFGF and I"GFI3  on the release of  HSPG by plas- 
minogen activation. Cultures of BCE cells were treated either with 
10 ng/ml of bFGF or with 4 ng/ml of TGF/3 in the presence  of 
3sSO4 for 16 h. After the labeling, the cells were washed, increas- 
ing amounts of plasminogen were added, and the cultures were in- 
cubated for 30 min at 37°C after which aprotinin (200 KIU/ml) was 
added to inhibit the formed plasmin.  Released HSPG molecules 
were isolated by immobilized bFGF, the samples were analyzed by 
a 3-16% SDS-PAGE, and the labeled molecules were visualized by 
autoradiography. (a-c) Cultures treated with bFGF; (d-f) cultures 
treated with TGF/~ (a and d)  1/~g/ml plasminogen;  (b and e)  10 
ttg/ml plasminogen; (c and f) 100/~g/ml plasminogen. To demon- 
strate the total amount of labeled plasmin-sensitive bFGF-binding 
HSPGs  in the  cultures,  10/~g/ml  of plasmin  was added to both 
bFGF-treated  (g) and TGF/~-treated (h) cells. 
present article, we show that the bFGF-binding HSPGs are 
located in the extracellular structures of BCE cells and sug- 
gest a mechanism for the release of these bFGF-binding mol- 
ecules and bFGF by the physiologically relevant protease, 
plasmin. The release of extracellular HSPGs can be modu- 
lated  by  factors  that  affect the  proteolytic  balance  in  the 
pericellular  environment.  This provides a  mechanism for 
controlling  bFGF  release  from  the  matrix  and/or  cell 
surface. 
The BCE cells seem to have two principal bFGF-binding 
HSPGs, which are located in separate compartments of the 
cell.  The larger 800-kD molecule remains attached to the 
dish after detergent extraction of the cultures and seems to 
be a component of the extracellular matrix. The smaller 250- 
kD molecule is readily dissolved by nonionic detergents and 
thus may represent a  membrane proteoglycan as described 
in some other cell culture models (20,  23). 
The extracellular matrix is considered to have an impor- 
tant  function  in  guiding  and  regulating  cell  morphology, 
growth, and differentiation in vivo. At sites of active tissue 
remodeling and growth, a primary and often dominant fea- 
ture is hydrolysis of matrix components via secretion of lytic 
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vine urokinase antibodies on the release 
of 35SO4-1abeled bFGF-binding  HSPG 
released by BCE cells. The cells were la- 
beled for 16 h, washed, and incubated in 
the presence  of 10 ttg/ml plasminogen 
(a-j)  and  200  KIU/ml aprotinin  (a); 
plasminogen alone (b); 5% nonimmune 
rabbit serum (c); 5% immune anti-bo- 
vine urokinase antiserum  (d); 50, 200, 
and 500/~g/ml  nonimmune  rabbit IgG 
(e-g, respectively); or 50, 200, and 500 
/zg/ml anti-bovine urokinase  IgG (h_j, 
respectively).  After  the  incubation, 
aprotinin was added, the released mole- 
cules  were  isolated  by protein  A-im- 
mobilized bFGF, the samples were ana- 
lyzed by a 3-16%  SDS-PAGE, and the 
labeled  molecules  were  visualized  by 
autoradiography. 
enzymes by the proliferating cells (31).  This may well lead 
to  the  release  of biologically  active fragments of the  de- 
graded  matrix  components  and  to  the  release  of matrix- 
bound  growth  factors.  The  soluble heparan  sulfate-bFGF 
complex is biologically active and does not bind to the low 
affinity matrix-binding sites as does the uncomplexed bFGF 
(43).  Thus, complex formation with heparan sulfate mole- 
cules would  facilitate the diffusion of the growth factor to 
more distant sites.  For example, release of bFGF from in- 
jured corneal epithelial basement membrane has been sug- 
gested to have a role in corneal neovascularization (12).  The 
basement  membrane  is  rich  in  heparan  sulfates,  and 
heparinase can release bFGF-related activity from isolated 
corneal membranes (12).  However, a  prominent feature of 
sterile chronic corneal ulcers is an increased plasmin activity 
detectable in the corneal fluid (44). Thus, a possible mecha- 
nism is the release of heparan sulfate-bFGF complexes by 
proteolysis rather than bFGF alone from the injured area. 
The complexed, biologically active bFGF is resistant to inac- 
tivation in the proteinase-rich milieu and could freely diffuse 
to the vascularized area to initiate corneal angiogenesis. 
PAs are serine proteinases found in several tissues in vivo 
and are synthesized by many cell types in vitro (6). We pro- 
pose that  the  activation  of the  abundant  proenzyme plas- 
Figure 8.  Release of 3~SO4-1abeled bFGF-binding 
HSPG after combined treatment  with TGFB and 
bFGE Cultures of BCE cells were pretreated ei- 
ther with  10 ng/ml of bFGF (a and b) or with 4 
ng/rrd of TGF/~ (e and f) or incubated in serum- 
free medium  (c,  d,  g,  and  h).  After  6  h,  new 
medium  containing the label,  10/~g/ml  of plas- 
minogen,  and bFGF or TGF/$ was added to the 
cultures (3 ng/ml of bFGF in a, c, and e; 10 ng/rrd 
of bFGF in b, d, and~  1 ng/ml of TGF/3 in g; 4 
ng/ml of TGFB in h). The cultures were further in- 
cubated for 16 h, and the media were collected. 
Aprotinin was added, the released molecules were 
isolated by protein A-immobilized bFGF, samples 
were analyzed by a 3-16% SDS-PAGE, and the la- 
beled molecules were visualized by autoradiogra- 
phy. Release of bFGF-binding HSPG after bFGF 
stimulation  (a-f) is less in the TGFB-pretreated 
cultures (e and f) than in cultures preincubated in 
medium alone (c and d) or with bFGF (a and b) 
and  is close to the  release  of HSPG in cultures 
treated with TGF/3 alone (g and h). 
Saksela and Rifkin Protease-catalyzed  Release ofbFGF  773 minogen mediates  the release  of HSPG  from extracellular 
structures and thereby promotes the release of bFGF in a bio- 
logically active and soluble form.  To demonstrate the effect 
of the level of expressed  PA activity on the release  of ex- 
tracellular HSPGs, we treated the cells either with bFGF to 
enhance PA level or with TGFB to suppress it (42).  Treat- 
ment of BCE cells with TGFB resulted in greatly diminished 
formation of plasmin and decreased degradation of the ma- 
trix heparan sulfate proteoglycans. Addition of purified IgG- 
antibodies against bovine urokinase in the incubation medi- 
um  during  collection  of the  metabolically  labeled  bFGF- 
binding  HSPGs  almost  completely  blocked  the  release  of 
these molecules from the cell layer.  It is interesting to note 
that pretreatment of cultures with TGF/3 blocks the stimula- 
tion  of the  cells  by  bFGF  (42).  Whether  this  interaction 
could  partly  result  from  decreased  proteolytic  activity 
caused by TGF~ treatment and subsequently from decreased 
availability of the matrix-bound bFGF  to the high affinity 
receptor (30) has not been documented.  However, we have 
now demonstrated  decreased  release  of HSPG  from  BCE 
cells  after  bFGF  stimulation  when  the  cells  have  been 
pretreated  for 6  h  with TGFB. 
A  role for proteolytic activity in cellular proliferation is 
suggested by an earlier publication by Bergman et al.  (4). 
Addition of a proteinase inhibitor, protease nexin I, to cul- 
tures of fibrosarcoma cells resulted in a decreased degrada- 
tion of isolated endothelial cell matrix by the fibrosarcoma 
cells plated on top of the matrix. Addition of protease nexin 
1  also  caused  a  decrease  in  the  proliferation  rate  of the 
fibrosarcoma cells. A possible explanation for this observa- 
tion is that a decrease  in matrix degradation results in de- 
creased release of growth-promoting peptides from the cell 
matrix.  Growth  factors,  which  induce  PAl-l,  such  as 
TGFB,  are known to act as effective  growth inhibitors in 
several experimental models (34).  Part of their action may 
well be stabilization of the matrix  structures via increased 
accumulation of proteinase inhibitors, such as PAI-1 (26) or 
the tissue  inhibitor of metalloproteinases  (9),  into the ex- 
tracellular space. The growth substratum in endothelial cells 
contains functionally active, stabilized PAI-1  (27, 28). This 
would result in decreased  release  of matrix-bound growth 
factors. 
The  plasminogen-plasmin  system  works  predominantly 
at cell-to-cell or cell-to-substrate contact areas (41). A close 
contact is required in many experimental models, where the 
differentiation or proliferation of one cell type is mediated 
by  the presence  of another cell.  Such  an  interaction  can 
clearly be demonstrated in the bone marrow, where differ- 
entiation of blood cells requires a cell-to-cell  contact with 
the local stromal fibroblasts (8, 13). Colony-stimulating fac- 
tors necessary for differentiation of the stem cells are sug- 
gested to bind to stromal cell matrix (14), and isolated heparan 
sulfate has been suggested to bind growth factors necessary 
for the stem cell proliferation (39). Thus, the degradation of 
the HSPG core protein by plasmin may be part of a more 
general mechanism by which growth-regulating factors are 
made available to cellular receptors. Regulation of the peri- 
cellular proteolytic activity could be of primary importance 
in this process. 
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